Nason Gregory J, Sweet Joan, Landoni Lauren, Leao Ricardo, Anson-Cartwright Lynn, Mok Spencer, Guzylak Vanessa, D'Angelo Andrea, Fang Zhi Yi, Geist Ilana, Warde Padraig, Jewett Michael A S, Hamilton Robert J
Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Department of Pathology and Lab Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
Can Urol Assoc J. 2020 Dec;14(12):411-415. doi: 10.5489/cuaj.6481.
We sought to evaluate the discrepancies between primary pathology report and second pathology review of radical orchiectomy (RO) specimens.
A retrospective review was performed of RO specimens from the Ontario Cancer Registry. All cases required both a primary pathology report and a second pathology review from another institution. Histopathological variables assessed included histological subtype and components of mixed germ cell tumor (GCT), pathological tumor (pT) stage, lymphovascular invasion (LVI), spermatic cord invasion, and surgical margin.
Between 1994 and 2015, 5048 ROs were performed with 2719 (53.9%) seminoma and 2029 (40.2%) non-seminoma. Of these, 519 (10.3%) received a second pathology review. There was concordance between primary pathology report and second pathology review in 326 (62.8%) cases. The most common discrepancies involved a change in pT stage (n=148, 28.5%), with upstaging in 83 (16%) and downstaging in 65 (12.5%) cases relative to the original pT stage. The second most common discrepancy regarded the reporting of LVI (n=121, 23.3%), with 62 (11.9%) reporting presence of LVI when the primary pathology report did not. Other discrepancies included a change in the histological subtype in 28 (5.4%) cases and spermatic cord margin status in five (9.6%) cases.
Only 10% of orchiectomy specimens underwent a second pathology review, with nearly 40% of reviews leading to a meaningful change in parameters. Such variation could lead to incorrect tumor staging, estimate of relapse risk, and inappropriate treatment decisions. Expert pathology review of RO specimens should be considered, as it has significant implications for decision-making.
我们试图评估根治性睾丸切除术(RO)标本的初次病理报告与二次病理复查之间的差异。
对安大略癌症登记处的RO标本进行回顾性研究。所有病例均需要初次病理报告以及来自另一家机构的二次病理复查。评估的组织病理学变量包括组织学亚型和混合性生殖细胞肿瘤(GCT)的成分、病理肿瘤(pT)分期、淋巴管浸润(LVI)、精索浸润和手术切缘。
1994年至2015年间,共进行了5048例RO手术,其中精原细胞瘤2719例(53.9%),非精原细胞瘤2029例(40.2%)。其中,519例(10.3%)接受了二次病理复查。326例(62.8%)病例的初次病理报告与二次病理复查结果一致。最常见的差异涉及pT分期的改变(n = 148,28.5%),相对于原始pT分期,83例(16%)病例分期上调,65例(12.5%)病例分期下调。第二常见的差异是LVI的报告(n = 121,23.3%),62例(11.9%)病例在初次病理报告未提及LVI时报告存在LVI。其他差异包括28例(5.4%)病例的组织学亚型改变和5例(9.6%)病例的精索切缘状态改变。
仅10%的睾丸切除标本接受了二次病理复查,近40%的复查导致参数有意义的改变。这种差异可能导致肿瘤分期错误、复发风险估计错误以及不适当的治疗决策。应考虑对RO标本进行专家病理复查,因为这对决策有重大影响。